ReviewJournal of neuro-oncology2026
Staging prognostic discussions about glioblastoma.
Review in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecular features of intratumoral hemorrhage in glioblastoma isocitrate dehydrogenase-wildtype.Journal of neuro-oncology · 2026Article
- Heterogeneity, Measurement, and Clinical Implications of Oxygenation, Cell Signaling, and Redox Biology in Glioblastoma and Adult Diffuse Gliomas, with Context from Other Brain Tumors.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundNeuro oncologists bear the responsibility of disclosing prognostic information to patients with glioblastoma. Despite this obligation, prognostic information is neither routinely nor effectively communicated.
methodsA narrative review of empiric data related to prognostic disclosure in cancer and in GBM is performed, and a normative framework based on this data and our own clinical and ethical experience and consideration is presented. ANALYSIS: The authors propose a framework of staged disclosure of prognostic information, where the incurability of glioblastoma and the likelihood of neurocognitive decline are discussed at the first patient encounter, but estimations of life expectancy are deferred until a subsequent visit. This approach pragmatically balances oncologists' obligation to preserve patient autonomy and prioritize advance care planning, while also aiming to prevent information overload, allowing the news to be delivered in the context of an increasingly trustful patient-physician relationship, and allowing for more accurate estimations in light of complete pathology results, which are not often available at the first visit.
conclusionStaged prognostic discussions about glioblastoma balance oncologists' ethical obligations and optimize communication of prognostic information to patients and their families. Further empirical studies implementing this approach are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.